Q3 2025 Inovio Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Inovio Pharmaceuticals Inc (INO) completed the rolling submission of their BLA for INO-3107, marking a significant milestone for the company.
- The company has requested a priority review for INO-3107, which could lead to a potential PDUFA date around mid-2026.
- INO-3107 demonstrated a 50% to 100% reduction in surgeries for most patients in clinical trials, highlighting its potential effectiveness.
- Inovio Pharmaceuticals Inc (INO) has reduced operating expenses by 22% year-over-year, demonstrating effective cost management.
- The company is advancing its next-generation DNA medicine candidates, with promising data published in Nature Medicine and upcoming presentations at global forums.
- Inovio Pharmaceuticals Inc (INO) reported a net loss of $45.5 million for the quarter, primarily due to noncash losses on warrant liabilities.
- The company's cash position decreased significantly, with $50.8 million in cash and equivalents compared to $94.1 million at the end of 2024.
- There is uncertainty regarding the competitive landscape, as Papzimeos has already launched, potentially impacting market share for INO-3107.
- The requirement for a confirmatory trial for INO-3107 could delay full FDA approval and impact timelines for ex-US approvals.
- Inovio Pharmaceuticals Inc (INO) anticipates a cash runway only into the second quarter of 2026, raising concerns about future funding needs.
Good afternoon, ladies and gentlemen, and welcome to the INOVIO third-quarter 2025 financial results conference call. (Operator Instructions) This call is being recorded on Monday, November 10, 2025.
And I would now like to turn the conference over to Jennie Willson. Thank you. Please go ahead.
Good afternoon, and thank you for joining the INOVIO third-quarter 2025 financial results conference call. Joining me today on today's call are Dr. Jacqui Shea, President and Chief Executive Officer; Dr. Mike Sumner, Chief Medical Officer; Peter Kies, Chief Financial Officer; and Steve Egge, Chief Commercial Officer.
Today's call will review our corporate and financial information for the quarter ended September 30, 2025, as well as provide a general business update. Following prepared remarks, we will conduct a question-and-answer session.
During the call, we will be making forward-looking statements regarding future events and the future performance of the company. These events
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
